ROCO
6677
Market cap35mUSD
Oct 08, Last price
20.50TWD
1D
4.06%
1Q
17.14%
IPO
-54.07%
Name
Anxo Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Anxo Pharmaceutical Co., Ltd. functions as a specialized enterprise in the pharmaceutical sector. This company is actively involved in the research, production, and global distribution of various medicinal products, catering to both healthcare professionals and individual patients, particularly within Taiwan and across international markets. Its comprehensive product catalog features both prescription-only drugs and over-the-counter remedies, addressing a broad spectrum of therapeutic needs. These include cardiovascular health, metabolic disorders, conditions affecting the central nervous system, diabetes management, respiratory ailments, anti-infective treatments, dermatological issues, nephrology, urology, and orthopedics, among others. More specifically, Anxo supplies agents for antidiabetic and dyslipidemic conditions, supports cardiovascular and circulatory systems, offers therapies for the nervous system, addresses hepatological and gastroenterological concerns, provides anti-infective and antiviral agents, and assists with hemodialysis and urinary system treatments. Additionally, their offerings cover respiratory system and antihistamine applications, various analgesics, and other specialized medications, including a range of injectable pharmaceuticals. Established in 2003, the company's main operational base is situated in Taipei, Taiwan.
Key people
Jerry Wang
Chairman of the Board · since 2024
Linquan Yan
Chief Executive Officer, General Manager, Director · since 2021
Yuwen Huang
Chief Information Security Officer · since 2024
Qiheng Jian
Chief Research & Development Officer · since 2022
Wenlong Li
Head of Finance & Accounting, Corporate Governance Officer · since 2024
Shujun Chen
Director · since 2017
Guangyang Xu
Director · since 2024
Chun-Cheng Chen
Independent Director · since 2018
Independent Director · since 2018
Zhaozhou Kang
Independent Director · since 2024
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||